GEMPHARMATECH USA

Company Overview

GemPharmatech is a leading contract research organization that provides genetically engineered mouse models (GEMMs) and services to global preclinical R&D communities. We specialize in developing animal models using cutting edge gene-editing technologies with a large collection of cKO/KO (conditional knockout/knockout) mice, humanized mice, immunodeficient mice, and germ-free mice.

GemPharmatech provides an expansive array of preclinical services, including mouse model customization, pharmacology services such as drug efficacy testing and mouse phenotyping, CRISPR/Cas9 gene-editing, cryopreservation, rapid expansion, and customized breeding. The GemPharmatech contract research organization has developed one of the world's largest collections of mouse models to enable scientific innovation and accelerate drug development.

Leadership Team

• 

  Mark W. Moore, PhD

  CHIEF EXECUTIVE OFFICER

  Mark is a pioneer in the use of genetically modified mice for pharmaceutical and basic research. He has worked in immunology, oncology, animal model construction and gene editing. Before joining GemPharmatech, he was a co-founder and CSO of Deltagen, the first high-throughput gene KO and target development company, and later served as the Executive Director of the International Mouse Phenotyping Consortium (IMPC). He received his Ph.D. in Biology from Brandeis University studying antibody gene recombination using transgenic mice.

• 

  Brook White

  SENIOR DIRECTOR, SALES AND MARKETING

  Brook has held senior marketing executive positions in a number of life sciences companies and has over 20 years of experience in the industry. Her prior experience includes working with companies in clinical trial technology, the clinical CRO space, and CDMO space.  She is responsible for leading GemPharmatech’s marketing and sales operations in the US.

• 

  Zhiying Li, PhD

  DIRECTOR, LIFE SCIENCE AND TECHNOLOGY

  Zhiying is a trained neuroscientist with a doctoral degree from Harvard University. She conducted her postdoctoral research at Rockefeller University. Prior to joining GemPharmatech, she worked at Taconic Biosciences, providing scientific support to both commercial products and scientific services. She is a firm believer in ethical use of research animals and their invaluable contribution to biomedical research for the benefit of human health.

• 

  Santi Suryani Chen, PhD

  ASSOCIATE DIRECTOR, IMMUNOLOGY AND ONCOLOGY

  Santi is a research scientist and business development professional with over 10 years of experience in autoimmune disease, immunology, and oncology disease areas. Santi received her training in human B cell development at the Garvan Institute of Medical Research Australia in Immunology, followed by a postdoctoral fellowship at the Children’s Cancer Institute Australia, focusing on pediatric leukemia and therapies. Her projects include testing agents' efficacy and mechanisms such as navitoclax, venetoclax, and selumetinib. Her research projects resulted in multiple publications in journals such as Blood and Journal of Immunology and national/international awards.